Johnson & Johnson logo

Johnson & Johnson (JNJ)

Market Closed
12 Aug, 20:00
NYSE NYSE
$
260. 89
+1.09
+0.4196%
After Hours
$
261. 48
+0.59 +0.2261%
620.77B Market Cap
29.06 P/E Ratio
0.69% Div Yield
3.26M Volume
9.91 Eps
$ 259.8
Previous Close
Add Transaction
Day Range
255.25 261.41
Year Range
172.7 274.9
Want to track JNJ and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Johnson & Johnson Just Paid Investors: Here's How Much They Got

Johnson & Johnson Just Paid Investors: Here's How Much They Got

Johnson & Johnson (NYSE: JNJ) is rewarding its shareholders once again with a quarterly dividend of $1.24, payable on Tuesday, March 4.

247wallst | 1 year ago
Why the Market Dipped But Johnson & Johnson (JNJ) Gained Today

Why the Market Dipped But Johnson & Johnson (JNJ) Gained Today

Johnson & Johnson (JNJ) reachead $167.28 at the closing of the latest trading day, reflecting a +1.37% change compared to its last close.

Zacks | 1 year ago
3 Top High-Yield Dividend Stocks I Plan to Buy in March for More Passive Income

3 Top High-Yield Dividend Stocks I Plan to Buy in March for More Passive Income

Generating passive income is a core aspect of my financial strategy. My goal is to eventually produce enough recurring investment income to cover my basic living expenses.

Fool | 1 year ago
3 Dividend Stocks That Are No-Brainer Buys Right Now

3 Dividend Stocks That Are No-Brainer Buys Right Now

It can be difficult to decide which dividend stocks to buy. After all, more than 5,700 of them trade on U.S. stock exchanges.

Fool | 1 year ago
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It

Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.

Zacks | 1 year ago
Johnson & Johnson (JNJ) Could Be a Great Choice

Johnson & Johnson (JNJ) Could Be a Great Choice

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?

Zacks | 1 year ago
Johnson & Johnson (JNJ) Ascends While Market Falls: Some Facts to Note

Johnson & Johnson (JNJ) Ascends While Market Falls: Some Facts to Note

In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $166.09, denoting a +1.44% change from the preceding trading day.

Zacks | 1 year ago
J&J sues Samsung Bioepis over contract breach for Stelara biosimilar

J&J sues Samsung Bioepis over contract breach for Stelara biosimilar

Johnson & Johnson said on Monday it had filed a lawsuit against Samsung Bioepis for breaching its contract agreement with the drugmaker over the launch of a biosimilar to Stelara, J&J's autoimmune drug.

Reuters | 1 year ago
2 Very Healthy High-Yield Dividend Stocks to Buy for a Safe and Growing Passive Income Stream

2 Very Healthy High-Yield Dividend Stocks to Buy for a Safe and Growing Passive Income Stream

A higher dividend yield is nice because it allows you to collect more dividend income on every dollar you invest in a stock. However, the company paying that dividend needs to be healthy to ensure it can maintain its payout during the tough times that inevitably come.

Fool | 1 year ago
Johnson & Johnson (JNJ) Up 8.9% Since Last Earnings Report: Can It Continue?

Johnson & Johnson (JNJ) Up 8.9% Since Last Earnings Report: Can It Continue?

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?

Zacks | 1 year ago
Johnson & Johnson (JNJ) Laps the Stock Market: Here's Why

Johnson & Johnson (JNJ) Laps the Stock Market: Here's Why

The latest trading day saw Johnson & Johnson (JNJ) settling at $157.89, representing a +1.87% change from its previous close.

Zacks | 1 year ago
J&J begins crucial battle over $10 billion baby powder settlement

J&J begins crucial battle over $10 billion baby powder settlement

Johnson & Johnson faces a critical test on Tuesday over its $10 billion proposal to end litigation alleging that its baby powder caused ovarian cancer, as it tries to convince a judge to sign off on its third attempt to resolve thousands of lawsuits through a subsidiary's bankruptcy.

Reuters | 1 year ago
Loading...
Load More